[Chemotherapy of Hodgkin's disease].
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004342:Drug Hypersensitivity; D004359:Drug Therapy, Combination; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D008466:Mechlorethamine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011034:Podophyllotoxin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011344:Procarbazine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012008:Recurrence; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001761:Bleomycin; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D014747:Vinblastine; D011034:Podophyllotoxin; D011241:Prednisone
La chimiothérapie de la maladie de Hodgkin